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Three of six morphine-dependent monkeys progressed rapidly to AIDS and died by 20 weeks in our SIV/SHIV non-human primate model of
drug addiction and AIDS. We studied the evolution of the SIV vpr gene in both cerebrospinal fluid (CSF) and plasma in these rapid progressors, in
their normal progressor counterparts and in infected, drug-free controls at 12 and 20 weeks post infection. Viral RNAwas amplified, cloned, and
sequenced to permit phylogenetic analyses of diversity and divergence of the vpr locus. As we found for SIV tat and env, the vpr gene evolves
inversely to the rate of disease progression. Further, we found evidence that compartmentalization of the virus in plasma and CSF is significantly
greater in the normal progressors than in the morphine-dependent, rapid progressors. Interestingly, although our previous work with the accessory
gene nef indicated no association between disease progression and evolution, the accessory factor, vpr, behaves similarly to the essential lentiviral
genes tat and env.
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All retroviruses share common elements in genomic
structure including the gag, pol, and env genes. In addition to
these universally essential genes the primate lentiviruses,
including both HIV-1 and SIV have a well-characterized set
of accessory gene products (Vogt, 1997). Only two of these
accessory genes, tat and rev, are absolutely required both in
vivo and in vitro for viral replication (Dull et al., 1998; Luciw,
1996). Another accessory gene, vpr (encoding the viral protein
R), is common to both HIV-1 and SIV, yet unlike the tat and rev
gene products, vpr has been shown to be dispensable for viral
replication in a number of cell culture and animal model settings
(Le Rouzic and Benichou, 2005; Aldrovandi and Zack, 1996).⁎ Corresponding author. Department of Biochemistry, Ponce School of
Medicine, 395 Zona Industrial Reparada, Ponce, PR 00716, USA. Fax: +1
787 841 1040.
E-mail address: rnoel@psm.edu (R.J. Noel).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.09.043In in vivo studies, however, a vpr-SIV is only half as virulent as
the wild type SIVmac239, while a deletion of two accessory
gene products, vpr and nef, is 99.5% less virulent and does not
lead to simian AIDS (Desrosiers et al., 1998), indicating the
importance of this ∼100aa protein.
Vpr is packaged in the virus via an association with the p6
component of the viral gag gene (Kondo et al., 1995; Paxton et
al., 1993). During viral replication, Vpr has been attributed a
variety of roles including increasing the accuracy of reverse
transcription, assisting in the nuclear import of the preintegra-
tion complex, transactivation of the viral promoter, regulation of
cell cycle and in some cells, regulation of apoptosis (Le Rouzic
and Benichou, 2005; Mueller and Lang, 2002; Patel et al., 2002;
Chen et al., 2004; Mahalingam et al., 1997; Muthumani et al.,
2002b; Piller et al., 1999; Di Marzio et al., 1995). In the specific
setting of SIV, some of the functions of Vpr (in HIV) are shared
or overlapping with SIV Vpx. However, at least the transactiva-
tion, apoptosis and cell cycle regulation appear to be conserved
in Vpr proteins of primate lentiviruses (Planelles et al., 1996;
398 R.J. Noel Jr., A. Kumar / Virology 359 (2007) 397–404Zhu et al., 2001; Philippon et al., 1999). Thus Vpr protein has
demonstrable roles in a variety of aspects of viral infection and
pathogenesis. Still, there is little information of the possible
pathogenic role of Vpr during the setting of drug abuse
regardless of the large impact of drugs of abuse on the HIV/
AIDS epidemic both in the US and worldwide.
In the US alone, drug abuse is a co-factor in the acquisition
and or pathogenesis in nearly 1/3 of the HIV-1 infection cases
(Purcell et al., 2004). Although this clearly presents a
considerable burden on the health care system and the economy,
studies of the impact of drug abuse (morphine) have provided
mixed message of harm (Chuang et al., 2005) versus reduced
pathogenesis (Donahoe, 2004; Kapadia et al., 2005). In part to
address this ongoing controversy, we have developed a non-
human primate model of AIDS/drug abuse using rhesus
macaques addicted to morphine and then infected with a
combination of viruses (SIV17E-Fr, SHIV89.6P, SHIVKU-1B) to
more rapidly induce simian AIDS (sAIDS), including a
precipitous loss in CD4+T cells characteristic of AIDS in
humans (Kumar et al., 2004a). In this model, we have observed
that half of the morphine addicted animals progress rapidly to
AIDS and death by 20 weeks post-infection (Table 1) (Kumar et
al., 2004a; Noel and Kumar, 2006). While all animals in the
study showed a rapid peak in virus and severe drop in CD4+T-
cells during the acute phase of infection, the rapid progressors
never regained CD4+T-cells; nor did they establish control of
the viral replication in either the plasma or the cerebrospinal
fluid (CSF) (Kumar et al., 2004a). Macaques that did not show
rapid progression, including half of the morphine group and all
members of the morphine-free cohort, established someTable 1
CD4+, viral load in plasma and cerebrospinal fluid
Monkey Sampling
week
CD4+T
(cells/mL)
plasma viral load
(104 copies/mL)
CSF viral load
(104 copies/mL)
Group A a
1/04L 12 16 401 37.3
18 2.9 3340 226
1/28N 12 21 2030 1150
20 6 7660 204
1/42N 12 39 2590 17.8
19 10 10,700 111
Group B
1/02N 14 31 3.63 0.052
18 10 6.62 0.012
1/52N 14 707 0.144 below limit
20 1365 0.022 below limit
1/56L 12 31 44.2 0.023
20 13 147 0.024
Group C
2/02P 12 113 3.14 0.140
18 447 3.35 0.008
2/31P 12 334 3.14 0.008
18 214 0.457 0.008
2/AC42 12 154 1.41 0.140
18 44 0.186 0.008
a No Group A monkeys survived beyond week 20 1/04L was euthanized at
week 18, 1/28Q at week 20 and 1/42N at week 19.recovery of CD4+T-cells and control over plasma and CSF
viral load. One goal of our work with these cohorts has been to
evaluate the impact of viral evolution in rapid progression in the
setting of drug abuse. We have already established a relation-
ship between viral evolution and the rate of disease progression
for a number of critical viral genes in this system. Both the
essential accessory gene tat (in plasma and in CSF) and the
structural gene env (plasma) have shown an inverse correlation
between evolution and disease progression in the setting of
morphine-dependence (Noel and Kumar, 2006; Noel et al.,
2006a, 2006b; Tirado and Kumar, 2006). However, our
experience to date with an in vitro dispensable accessory gene
(nef) showed no correlation between evolution rate and disease
progression (Noel et al., 2006a, 2006b). This suggested that
some non-essential accessory genes could prove less influential
to rapid pathogenesis. We have now extended this analysis to
the vpr gene where we find that unlike the dispensable
accessory gene nef, and like the essential accessory gene tat,
evolution is inversely correlated to disease progression both in
plasma and CSF, and furthermore, that compartmentalization of
virus does not occur in rapid progression.
Results and discussion
Rate and complexity of evolution of vpr correlate inversely with
disease progression
As with our previous studies, viral nucleic acids were
extracted for two times points roughly 12 and 20 weeks post
infection from cell-free fluids and subjected to RT-PCR
amplification, cloning and sequencing (Noel and Kumar,
2006; Noel et al., 2006a, 2006b; Tirado and Kumar, 2006).
Phylogenetic comparisons were made of all clones in both
plasma and CSF within each individual monkey. The resulting
phylogenetic trees (Fig. 1) show that vpr evolution appears to
be inversely correlated with disease progression. Each tree
includes the sequence of the SIV virus used in the initial
infection (inoculum) as well as the original SIV17E-Fr
sequence (Genebank #AY033146). Although all three inoculum
virus have identical Vpr amino acid sequences there are silent
nucleotide changes present in the SHIVs. We found no evidence
in our clones for amplification of vpr from either SHIV,
indicating that our primers were specific for SIVas was the case
for tat (Noel and Kumar, 2006; Noel et al., 2006a, 2006b). We
found no evidence of recombination among the three viral
forms as we did for nef (Noel et al., 2006a, 2006b), thus we did
not include the SHIVs in our trees. Interestingly, as we observed
for tat, the clustering patterns of the trees were more evident in
normal progressors (Fig. 1, Groups B and C), and in particular
with CSF samples as opposed to the plasma (Noel et al., 2006a,
2006b). Thus, not only does evolution appear to be inversely
correlated with rate of disease progression, but the complexity
of the evolution and the ability of a variant to start a persistent
evolutionary path appear to be related to slower progression
rather than the presence of morphine itself (compare Group A
vs. B and C, Fig. 1). Recent studies that show no detectable
binding or neutralizing antibodies nor virus specific CTL
Fig. 1. Phylogenetic trees were made for each individual animal and included plasma (filled symbols) and CSF (open symbols) clones that were divergent from the
inoculum clone (open triangle). Group A are morphine-dependent rapid progressors; Group B are morphine-dependent normal progressors; and Group C are control,
non-morphine normal progressors. Clones are from 12 weeks (circles) or 20 weeks (squares) post infection. All trees were drawn to the same scale provided in the
legend. The sequence for the original SIV17E-Fr (accession #AY033146) was used to root each tree (filled triangle). The scale bar in each tree represents 0.5%
distance, or 1 change per 200 nucleotides. Bootstrap values, based on 100 replicates, that are greater than 70 are included. All sequences in this study were deposited
into Genebank (DQ839744–DQ840024).
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in normal progressors (Kumar et al., 2006), are suggestive of a
role for immune pressure in the enhanced compartmentalization
we detected for both tat (earlier) and vpr in this work.
SIV vpr diversity and divergence are less in
morphine-dependent rapid progressors
Similar to what has been reported for tat and the 5′ part of
env (Noel and Kumar, 2006; Noel et al., 2006a, 2006b; Tirado
and Kumar, 2006), the SIV vpr gene had the lowest overall
diversity in Group A (Fig. 2). The average diversity of all clones
was significantly lower in the rapid progressors than in all
normal progressors (Fig. 2A, 0.31% Group A vs. 0.59% GroupB+ C, p<0.05) as well as compared to the normal progressor,
morphine dependent group alone (0.31% Group A vs. 0.64%
Group B, p<0.05). Diversity was the lowest in Group A
animals in both plasma and CSF when compared only in those
compartments (Figs. 2B and C); however, the trend did not
achieve statistical significance.
The vpr divergence in rapid progressors was also signifi-
cantly less than in all normal progressors (Group A 0.16% vs.
Groups B+ C 0.34%, p<0.05, Fig. 3A). Further, the divergence
was significantly less than either Group B (0.16% vs. 0.35%,
p<0.05, Fig. 3A) or Group C (0.16% vs. 0.32%, p<0.05,
Fig. 3A) when all samples from both plasma and CSF were
considered; as well as versus Group C specifically in the CSF
(0.19% vs. 0.39%, p<0.05, Fig. 3C). Divergence in plasma
Fig. 2. For each animal, the sequenced clones for all samples (A), plasma only (B), or CSF only (C) were aligned (BioEdit) and a distance matrix was calculated (Mega,
3.0). The means of these distances for each time is plotted versus time for Group A: 1/04 L, 1/28Q, 1/42N , Group B: 1/02N, 1/52N, 1/56 L, and Group C: 2/02P, 2/31P,
2/AC42 to show the overall diversity of clones within each macaque including all times. Standard errors are indicated for each animal. Statistical differences in
diversity between Groups were calculated by Student's t-test (Noel and Kumar, 2006; Noel et al., 2006a, 2006b). A value of 0.05 was set as the level of significance.
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in normal progressors (Fig. 3B).
Compartmentalization of virus occurs only in normal disease
progression
The relationship between the full array of vpr sequence
changes within an individual animal (the total diversity) and the
evolution of the viral population from the origin sequence
(divergence from the inoculum) was characterized by two
measures. First, we compared the ratio between diversity to
divergence within each monkey. This ratio was always the
greatest (near 2.0) in the rapid progressors, including all samples
(Fig. 4A), plasma only (Fig. 4B) and CSF only (Fig. 4C). In
comparisons with rapid progressors, the ratio of diversity to
divergence is statistically less for Groups B or C, with the singleFig. 3. The divergence of the clones within each animal from the inoculum for all s
Standard error values are indicated by the error bars and significance of differencesexception of Group C plasma for which data from one animal, 2/
AC42, was unavailable. As a second measure, we assessed the
divergence between the plasma and CSF populations in all three
groups (Fig. 3D). The divergence was significantly greater in
both Groups B and C as compared to Group A for all samples
(Fig. 3D, p<0.05). This indicates a greater degree of specific
selection of virus in these compartments in normal disease
progression. Although we did not find evidence of different
immune pressure by comparing the rates of synonymous/non-
synonymous mutations (data not shown) as was the case for tat
previously (Noel and Kumar, 2006; Noel et al., 2006a, 2006b),
the greater divergence between plasma and CSF in Groups B and
C suggests a different level of selective pressure, including the
possibility of the emergence of a functional immune response. In
fact, none of the Group A animals developed detectable virus-
specific immunity, while both Group B and C macaques showedamples (A), plasma only (B), or CSF only (C) were calculated using Mega 3.0.
in divergence (Student's t-test) are indicated in each graph.
Fig. 4. The ratio of diversity to divergence for each macaque was calculated by dividing the mean diversity by the mean divergence as calculated for Figs. 3 and 4.
These ratios were calculated for all samples (A), plasma only (B) and CSF only (C) and significant difference between the means of each group were calculated by
Student's t-test. In (D), the divergence between all plasma clones and all CSF clones within each individual macaque was calculated using Mega 3.0. Standard errors
are also graphed and statistical significance is indicated. Please note that the axis for (D) is to the right of the graph and that the scale is different than for (A–C).
401R.J. Noel Jr., A. Kumar / Virology 359 (2007) 397–404evidence of a specific immune response to SIV, including
binding and neutralizing antibodies as well as virus-specific
CTL (Kumar et al., 2006).
Changes at the amino acid level do not appear to predict
different rates of disease progression
Work reported previously by a number of groups have
indicated the functional regions of Vpr responsible for a variety
of the biological roles of this conserved lentiviral protein. For
example, both the transactivation and cell cycle arrest functions
are compromised by a change from arginine to serine at position
73(Sawaya et al., 2000). Cell cycle arrest can also be
compromised by alteration of the c-terminus (amino acids 83–
89) and at least once such mutations have been linked to long-
term non-progression (Wang et al., 1996). We examined the
deduced amino acid sequences for all vpr clones with unique,
non-synonymous mutations (Fig. 5) to determine if we could
find evidence of early changes in known functional domains
leading to slowed progression. No qualitative differences are
readily evident among the three groups in terms of absolute
number nor distribution of amino acid substitutions. Further-
more, R73 described previously by Sawaya et al. is universally
conserved in our clones. Interestingly, only monkeys in Groups
B and C show any changes between 83 and 89 amino acids, that
may be involved in G2 arrest (Wang et al., 1996), however, these
mutants were not a majority for any macaque.
Conclusions
This work examines, for the first time, the evolution of the
SIV vpr gene during rapid progression to simian AIDS in the
setting of morphine abuse. Much like the SIV tat gene in both
plasma and CSF or SIV env in plasma, evolution of vpr shows a
significant inverse correlation with disease progression. As with
tat, the virus appears to show compartmentalization only when
disease progression occurs at a normal rate, regardless of themorphine status. This is supported both in the trees and in a
direct comparison of the divergence between plasma and CSF
viral populations which was significantly less in the rapid than in
the normal progressors. In addition, in this report we provide the
first direct comparison of the ratio of diversity to divergence for
rapid and normal progressors. In all cases the total population
diversity was greater than the average evolution away from the
inoculum (divergence); however, the ratio was statistically
greater in the rapid progressors, perhaps suggesting that
biological selection had begun to promote evolution of particular
branches from among the viral quasispecies only in the normal
progressors. In fact, only in normal progressors was there any
evidence of a modest immune response by 20 weeks post-
inoculation (Kumar et al., 2006), indicating that immune
selection may have contributed to the reduced diversity to
divergence ratio. In contrast to the accessory gene product Nef
(Noel et al., 2006a, 2006b), this study provides the first
indication that the evolution is related to rapid disease
progression during drug abuse for a gene product that is
dispensable in vitro.
Previous work with HIV-infected humans has indicated that
the evolution of Vpr is related to long-term nonprogression (Cali
et al., 2005). Some long-term survivors have shown predomi-
nantly intact and functional vpr sequences, while lack of
progression in an injecting drug user was associated with subtle
changes in nef and the G2 arrest domain in the c-terminus of vpr
(Saksena et al., 1996; Zhang et al., 1997). Thus, the role of vpr
evolution in slow disease progression in humans may be distinct
from that of rapid disease in our model, although the study of an
individual drug user may lend a parallel to our system as we
carry out analysis beyond 20weeks. Perhaps a better comparison
can be made with studies of the role of vpr sequence changes on
HIV transmission. In this case, viral vpr sequences showing
greater hetereogeneity proved less infectious during vertical
transmission (Yedavalli and Ahmad, 2001), perhaps due to
greater likelihood of loss of important functional components of
the Vpr protein (Yedavalli et al., 1998). In these studies as well as
Fig. 5. The vpr coding sequences were translated to amino acids using BioEdit. Only sequences with nucleotide changes causing an amino acid substitution (non-
synonymous change) are included in each group. SIV7E-Fr and serves as the reference within each group. Each sequence is represented by animal week-clone in the
left column and all changes from 17E are indicated in the right column. The number of clones for each unique amino acid sequence is indicated in parenthesis to the
right of each sequence name. Positions of identity are indicated by a dot (.), frameshift mutations are indicated by (X) and stop codons by an asterisk.
402 R.J. Noel Jr., A. Kumar / Virology 359 (2007) 397–404our own work, greater virulence is associated with greater
conservation of the infecting form.
The lack of humoral responses to Vpr have also been
implicated in rapid progression (Richardson et al., 2003). Thus
the well known roles in immune interference (Muthumani et al.,2002a)and T cell apoptosis (Muthumani et al., 2002b)played by
Vpr in vivo may be involved in our system, even though we are
looking predominantly at rapid pathogenesis. We do see greatly
depleted levels of CD4+ T cells and, predominantly in the rapid
progressors, we have reported a failure to mount any detectable
403R.J. Noel Jr., A. Kumar / Virology 359 (2007) 397–404immune response (Kumar et al., 2006). Although, these data do
not clearly define the spectrum of amino acid changes that
differentiate our rapid from our normal progressors, based on
the pathogenicity of the inoculum virus and the more rapid rate
of change in the normal progressors, it is possible that the
mutations that occur within the first 20 weeks of infection in
normal progressors contribute to the slower progression in their
respective hosts beyond this time period.
Finally, although we still cannot describe the full role of
morphine in our system, we do find that only morphine-
dependent monkeys progress rapidly, and at a rate of 50%. A
picture is emerging that the evolution of some (tat, env, vpr) but
not all (nef) viral genes is directly related to the rate of
pathogenesis in the setting of drug abuse, but the cause effect
relationship is unclear. Morphine has well characterized effects
on cells of the immune system, but in spite of years of study,
there remains the question of the role of morphine in HIV
progression – whether it advances or prolongs the time to (and
severity of) AIDS. Our current work does suggest, as with tat
and env, that vpr evolution is a potentially important component
of early determination of disease progression and rapid
pathogenesis in morphine-dependent AIDS.
Materials and methods
Animal model
This study used a previously described rhesus macaque
model of drug abuse and AIDS (Kumar et al., 2004a; Noel and
Kumar, 2006). Nine male monkeys (Macaca mulatta) were
divided into morphine-dependent (N=6) or non-morphine
controls (N=3). Prior to viral infection, morphine was
administered for 18 weeks (5 mg/kg, T.I.D.) following a period
of morphine introduction with gradual dose increase from 1 to
5 mg/kg over 2 weeks (Kumar et al., 2004a). Morphine
administration was maintained throughout the study to avoid
withdrawal effects. Infection was by intravenous route with
a 2 mL inoculum containing 104 50% tissue culture infective
doses each of simian-human immunodeficiency virus KU-1B
(SHIVKU-1B), (Singh et al., 2002) SHIV89.6P,(Reimann et al.,
1996) and SIV 17E-Fr (SIV/17E-Fr)(Flaherty et al., 1997). This
three-virus combination produces uniform disease leading to
clinicalAIDS ina relatively short time (Kumar et al., 2002). In this
group of animals, the SIV 17E-Fr virus shows the greatest tissue
distribution and generates the predominant immune response
(Kumar et al., 2006). All animal protocols were approved by the
local animal care committee (IACUC) in accordance with the
Guide for the Care and Use of Laboratory Animals.
Amplification, cloning and sequencing of 5′ exon of tat
Viral RNA was extracted from cell-free fluids (plasma and
CSF) at approximately 12 and 20 weeks post infection. In cases
where samples were unavailable, samples at 14 or 18 weeks
served as substitutes. Primers (specific for SIV 17E-Fr) and
PCR conditions were as reported previously (Noel and Kumar,
2006; Noel et al., 2006a, 2006b). Briefly, an RT-PCR reaction(primers F1 5′-GGCAGGGGGATGGAGACCAGG and R1 5′-
GCACAAAAAAGGGGAATTGTCGC) was followed by a
secondary PCR reaction (primers F2 5′-AAATGAAGGACCA-
CAAAGGGAACC and R2 5′-CCCATAGACACTTAAAAG-
CAAGATGGC) to generate a 491 base pair DNA fragment. The
5′ end of this product, that encodes the C-terminal 94 amino
acids of the SIV Vpr protein, was sequenced after cloning into
pPCR2.1 (Invitrogen, Carlsbad, CA). A target of 6–10 positive
clones per time point were sent for sequencing to the DNA
Sequencing Facility of Florida State University, Department of
Biological Sciences. In general, two or more independent PCR/
cloning reactions were used to generate sufficient clones. All
sequences in this study were deposited into Genebank
(DQ839744–DQ840024).
Sequence editing and alignment and statistics
Sequence files (*.ab1 format) were decoded and edited using
BioEdit version 7.0.1(Hall, 1999). Alignments were performed
using BioEdit after removal of primer sequences and included the
282 nucleotides encoding the final 94 amino acids of SIV Vpr.
Amino acid sequences were inferred by translation of the
nucleotide alignments using the standard genetic code. Intraindi-
vidual diversity for all clones as well as divergence from the
inoculum clone were calculated using MEGA3.1(Kumar et al.,
2004b). Phylogenetic trees were formed using a neighbor-joining
method (Saitou and Nei, 1987). Group diversity and divergence
were compared statistically using an unpaired t-test. The statistical
cut-off for significance in these analyses was p=0.05.
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